Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The targeted therapies led to an 87% reduction in disease progression or death for newly diagnosed chronic lymphocytic leukemia patients.
About 1 in 4 adults and children treated with revumenib, new type of targeted therapy, achieved complete remission.
September was designated as National Blood Cancer Awareness Month in 2010 by United States Congress.
CAR-T expert Terry Fry of the University of Colorado Cancer Center talks about new data and future applications for this immunotherapy.
Two years after the Be the Match connection, he traveled to Germany to thank her in person for saving his life.
Findings show benefits of AI-driven techniques, chemotherapy-free treatments, and cell therapy.
Nearly three quarters of treated patients experienced partial disease regression.
Shivani Srivastava receives NCI MERIT Award to investigate how to improve engineered cancer immunotherapies against solid tumors.
Colorado University Cancer Center’s Jonathan Gutman, MD, treated Chen with a stem cell transplant for his acute myeloid leukemia.
EBV causes chromosome breakage that can trigger a cascade of genomic instability leading to tumor growth.
Novel treatment relies on a newer form of CRISPR gene-editing technology called base editing.
University of Colorado experts discuss the drugs Scemblix and Tecartus and the broader context of leukemia research today.
The Leukemia & Lymphoma Society’s Dare to Dream project helps pediatric cancer patients like Cayden, who received CAR-T therapy.
“I envision LLS continuing to be a leading innovator, driving change that impacts all cancer care,” says E. Anders Kolb, MD.
That’s a new blood cancer diagnosis approximately every three minutes.
The drug shortage has impacted 93% of surveyed cancer centers, according to the National Comprehensive Cancer Network.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.